trending Market Intelligence /marketintelligence/en/news-insights/trending/kwyjvdych5vpiipzmh4r_a2 content esgSubNav
In This List

Amgen's Repatha gets nod for expanded European approval

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Amgen's Repatha gets nod for expanded European approval

Amgen Inc. said the European Commission expanded the approval of its cholesterol drug Repatha to prevent heart attack and stroke in adults with certain forms of cardiovascular disease.

Results of a late-stage clinical trial showed that the drug reduced risk of heart attack by 27%, the risk of stroke by 21% and risk of coronary revascularization by 22%.

The new indication is for adults with established atherosclerotic cardiovascular disease such as myocardial infarction, stroke or peripheral arterial disease and is meant to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol levels.

The company previously secured the same expanded approval by the U.S. Food and Drug Administration in December 2017.

Repatha global sales grew 151% to $123 million during the first quarter of 2018, up from $49 million in the prior-year period.